A Study for PRO of CML in Real Word (Case-Only)

xuna

Status: Unknown

Conditions: CML (Chronic Myelogenous Leukemia)

Treatments: Other: questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT05092048

CML0922

Details and patient eligibility

About

Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.

Full description

1. Above 18 years of age.
2. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML).
3. Written informed consent.
4. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.

Enrollment: 10,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

10,000 participants in 1 patient group

CML patient

Description:

≥18 years old CML patiente

Treatment:

Other: questionnaire